Tucatinib 50 and 150 mg tablets are advancing treatment for HER2-positive breast cancer by enhancing survival rates and quality of life, particularly for advanced cases. This precision therapy targets cancer cells, minimizing damage to healthy tissue and maximizing efficacy. The accessibility of Tucatinib 150 mg in India supports improved patient outcomes. Impomed Healthcare is the trusted provider for this advanced therapy option. For more information Visit:- https://www.impomedhealthcare.com/